Oldest pages

Jump to navigation Jump to search

Showing below up to 50 results in range #4,551 to #4,600.

View (previous 50 | next 50) (20 | 50 | 100 | 250 | 500)

  1. Powner D, et al. Biochem. Soc. Trans. (2011) cited as Ref 753 in DOI: 10.1038/s41392-020-0110-5‏‎ (15:13, 20 May 2020)
  2. Ohnuma K, et al. Trends Immunol. (2008) cited as Ref 754 in DOI: 10.1038/s41392-020-0110-5‏‎ (15:13, 20 May 2020)
  3. Ghuwalewala S, et al. Stem Cell Res. (2016) cited as Ref 755 in DOI: 10.1038/s41392-020-0110-5‏‎ (15:13, 20 May 2020)
  4. Ming XY, et al. Nat. Commun. (2016) cited as Ref 756 in DOI: 10.1038/s41392-020-0110-5‏‎ (15:13, 20 May 2020)
  5. Burkin DJ, et al. Cell Tissue Res. (1999) cited as Ref 757 in DOI: 10.1038/s41392-020-0110-5‏‎ (15:13, 20 May 2020)
  6. Goldie SJ, et al. Int. J. Mol. Sci. (2019) cited as Ref 758 in DOI: 10.1038/s41392-020-0110-5‏‎ (15:13, 20 May 2020)
  7. Xu R, et al. JAMA Dermatol. (2016) cited as Ref 759 in DOI: 10.1038/s41392-020-0110-5‏‎ (15:13, 20 May 2020)
  8. Ghosh N, et al. Cancer Lett. (2009) cited as Ref 760 in DOI: 10.1038/s41392-020-0110-5‏‎ (15:13, 20 May 2020)
  9. Matsui W, et al. Cancer Res. (2008) cited as Ref 761 in DOI: 10.1038/s41392-020-0110-5‏‎ (15:13, 20 May 2020)
  10. O'Connell FP, et al. Am. J. Clin. Pathol. (2004) cited as Ref 762 in DOI: 10.1038/s41392-020-0110-5‏‎ (15:13, 20 May 2020)
  11. Borst J, et al. Curr. Opin. Immunol. (2005) cited as Ref 763 in DOI: 10.1038/s41392-020-0110-5‏‎ (15:13, 20 May 2020)
  12. Huang RX, et al. Oncotarget (2017) cited as Ref 764 in DOI: 10.1038/s41392-020-0110-5‏‎ (15:13, 20 May 2020)
  13. Liu SY, et al. Oncotarget (2013) cited as Ref 765 in DOI: 10.1038/s41392-020-0110-5‏‎ (15:13, 20 May 2020)
  14. Su J, et al. Arch. Med. Res. (2011) cited as Ref 766 in DOI: 10.1038/s41392-020-0110-5‏‎ (15:13, 20 May 2020)
  15. Zhuang HW, et al. Oncol. Rep. (2013) cited as Ref 767 in DOI: 10.1038/s41392-020-0110-5‏‎ (15:13, 20 May 2020)
  16. Wu AB, et al. Cancer Lett. (2013) cited as Ref 768 in DOI: 10.1038/s41392-020-0110-5‏‎ (15:13, 20 May 2020)
  17. Yang CH, et al. PLoS ONE (2014) cited as Ref 769 in DOI: 10.1038/s41392-020-0110-5‏‎ (15:13, 20 May 2020)
  18. Greco A, et al. Eur. Arch. Oto Rhino Laryngol. (2016) cited as Ref 770 in DOI: 10.1038/s41392-020-0110-5‏‎ (15:13, 20 May 2020)
  19. Zhou L, et al. Laryngoscope (2007) cited as Ref 771 in DOI: 10.1038/s41392-020-0110-5‏‎ (15:13, 20 May 2020)
  20. Targeting cancer stem cell pathways for cancer therapy (DOI: 10.1038/s41392-020-0110-5)‏‎ (20:56, 21 May 2020)
  21. Bibliography (from DOI: 10.1038/s41392-020-0110-5)‏‎ (23:22, 21 May 2020)
  22. Matsvay A (2nd author of DOI 10.3390/v12020211)‏‎ (20:27, 22 May 2020)
  23. Abramov I (3rd author of DOI 10.3390/v12020211)‏‎ (20:27, 22 May 2020)
  24. Dedkov V (4th author of DOI 10.3390/v12020211)‏‎ (20:27, 22 May 2020)
  25. Shipulin G (5th author of DOI 10.3390/v12020211)‏‎ (20:27, 22 May 2020)
  26. Khafizov K (6th author of DOI 10.3390/v12020211)‏‎ (20:27, 22 May 2020)
  27. Kiselev D (1st author of DOI 10.3390/v12020211)‏‎ (20:32, 22 May 2020)
  28. Section 3.2.1: Wnt signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5)‏‎ (11:24, 23 May 2020)
  29. Section 2.2: Isolation and identification of CSCs (from DOI: 10.1038/s41392-020-0110-5)‏‎ (11:34, 23 May 2020)
  30. Section 1: Introduction (from DOI: 10.1038/s41392-020-0110-5)‏‎ (11:35, 23 May 2020)
  31. Section 2: The concept of CSCs (from DOI: 10.1038/s41392-020-0110-5)‏‎ (11:36, 23 May 2020)
  32. Section 2.1: Biological characteristics of CSCs (from DOI: 10.1038/s41392-020-0110-5)‏‎ (11:36, 23 May 2020)
  33. Section 3: Factors regulating CSCs (from DOI: 10.1038/s41392-020-0110-5)‏‎ (11:37, 23 May 2020)
  34. Section 3.1: Major transcription factors in CSCs (from DOI: 10.1038/s41392-020-0110-5)‏‎ (11:37, 23 May 2020)
  35. Section 3.2: Major signaling pathways in CSCs (from DOI: 10.1038/s41392-020-0110-5)‏‎ (11:37, 23 May 2020)
  36. Section 3.2.2: Notch signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5)‏‎ (11:38, 23 May 2020)
  37. Section 3.2.3: Hh signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5)‏‎ (11:40, 23 May 2020)
  38. Section 3.2.4: NF-kappaB signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5)‏‎ (11:40, 23 May 2020)
  39. Section 3.2.5: JAK-STAT signaling pathway (from DOI: 10.1038/s41392-020-0110-5)‏‎ (11:41, 23 May 2020)
  40. Section 3.2.8: PPAR signaling pathways in CSCs (from DOI: 10.1038/s41392-020-0110-5)‏‎ (11:49, 23 May 2020)
  41. Section 3.2.9: Interactions between signaling pathways in CSCs (from DOI: 10.1038/s41392-020-0110-5)‏‎ (11:50, 23 May 2020)
  42. Section 3.3.1: Vascular niche microenvironments and CSCs (from DOI: 10.1038/s41392-020-0110-5)‏‎ (11:51, 23 May 2020)
  43. Section 3.3.2: The hypoxia microenvironment and CSCs (from DOI: 10.1038/s41392-020-0110-5)‏‎ (11:53, 23 May 2020)
  44. Section 3.3.3: Tumor-associated macrophages and CSCs (from DOI: 10.1038/s41392-020-0110-5)‏‎ (11:53, 23 May 2020)
  45. Section 3.3.4: Cancer-associated fibroblasts and CSCs (from DOI: 10.1038/s41392-020-0110-5)‏‎ (11:54, 23 May 2020)
  46. Section 3.3.5: Cancer-associated MSCs and CSCs (from DOI: 10.1038/s41392-020-0110-5)‏‎ (11:54, 23 May 2020)
  47. Section 3.3.6: Extracellular matrix and CSCs (from DOI: 10.1038/s41392-020-0110-5)‏‎ (11:54, 23 May 2020)
  48. Section 3.3.7: Exosomes in the TME and CSCs (from DOI: 10.1038/s41392-020-0110-5)‏‎ (11:55, 23 May 2020)
  49. Section 4: Therapeutic targeting of CSCs (from DOI: 10.1038/s41392-020-0110-5)‏‎ (11:56, 23 May 2020)
  50. Section 4.2: Agents targeting CSC-associated signaling pathways in clinical trials (from DOI: 10.1038/s41392-020-0110-5)‏‎ (12:00, 23 May 2020)

View (previous 50 | next 50) (20 | 50 | 100 | 250 | 500)

Retrieved from "http://wikibase.slis.ua.edu/wiki/Special:AncientPages"